Vivos Therapeutics Stock Forecast
NASDAQ: VVOSHealth CareMedical/Dental InstrumentsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 0.148 -1.00%
VVOS analyst consensus
Consensus (3 analysts)
none
Avg. price target
$2.12+1318.06%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Vivos Therapeutics (2026-10-09), 2 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $2.12, with a high estimate of $3.10 and a low estimate of $0.75. The average target implies upside of 1318.1% from the current price of $0.1495.
The spread between the highest and lowest targets is 313.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VVOS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 67% |
| Hold | 1 | 33% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $0.75 | +401.67% |
| Average target | $2.12 | +1318.06% |
| High target | $3.10 | +1973.58% |